Get quick answers to your questions about the article from our AI researcher chatbot
{'id': 'https://openalex.org/W4319333649', 'doi': 'https://doi.org/10.4155/tde-2022-0066', 'title': 'Industry Update, October 2022', 'display_name': 'Industry Update, October 2022', 'publication_year': 2023, 'publication_date': '2023-01-01', 'ids': {'openalex': 'https://openalex.org/W4319333649', 'doi': 'https://doi.org/10.4155/tde-2022-0066', 'pmid': 'https://pubmed.ncbi.nlm.nih.gov/36748673'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://doi.org/10.4155/tde-2022-0066', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S89829989', 'display_name': 'Therapeutic Delivery', 'issn_l': '2041-5990', 'issn': ['2041-5990', '2041-6008'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320316', 'host_organization_name': 'Future Science Ltd', 'host_organization_lineage': ['https://openalex.org/P4310320316'], 'host_organization_lineage_names': ['Future Science Ltd'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref', 'pubmed'], 'open_access': {'is_oa': True, 'oa_status': 'green', 'oa_url': 'https://arrow.tudublin.ie/context/scschcpsart/article/1154/viewcontent/Industry_Update_October_2022.pdf', 'any_repository_has_fulltext': True}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5089590514', 'display_name': 'Elaine Harris', 'orcid': 'https://orcid.org/0000-0003-1538-9947'}, 'institutions': [{'id': 'https://openalex.org/I4210144925', 'display_name': 'Technological University Dublin', 'ror': 'https://ror.org/04t0qbt32', 'country_code': 'IE', 'type': 'education', 'lineage': ['https://openalex.org/I4210144925']}], 'countries': ['IE'], 'is_corresponding': True, 'raw_author_name': 'Elaine Harris', 'raw_affiliation_strings': ['School of Chemical & BioPharmaceutical Science, Technological University DublinD07 EWV4Dublin, Ireland'], 'affiliations': [{'raw_affiliation_string': 'School of Chemical & BioPharmaceutical Science, Technological University DublinD07 EWV4Dublin, Ireland', 'institution_ids': ['https://openalex.org/I4210144925']}]}], 'countries_distinct_count': 1, 'institutions_distinct_count': 1, 'corresponding_author_ids': ['https://openalex.org/A5089590514'], 'corresponding_institution_ids': ['https://openalex.org/I4210144925'], 'apc_list': None, 'apc_paid': None, 'fwci': 0.0, 'has_fulltext': False, 'cited_by_count': 0, 'citation_normalized_percentile': {'value': 0.0, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 0, 'max': 71}, 'biblio': {'volume': '14', 'issue': '1', 'first_page': '11', 'last_page': '16'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10878', 'display_name': 'Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated proteins', 'score': 0.9573, 'subfield': {'id': 'https://openalex.org/subfields/1312', 'display_name': 'Molecular Biology'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10878', 'display_name': 'Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated proteins', 'score': 0.9573, 'subfield': {'id': 'https://openalex.org/subfields/1312', 'display_name': 'Molecular Biology'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}, {'id': 'https://openalex.org/T12786', 'display_name': 'Frugal Innovation in Emerging Markets', 'score': 0.9298, 'subfield': {'id': 'https://openalex.org/subfields/1403', 'display_name': 'Business and International Management'}, 'field': {'id': 'https://openalex.org/fields/14', 'display_name': 'Business, Management and Accounting'}, 'domain': {'id': 'https://openalex.org/domains/2', 'display_name': 'Social Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/pandemics', 'display_name': 'Pandemics', 'score': 0.449208}], 'concepts': [{'id': 'https://openalex.org/C144133560', 'wikidata': 'https://www.wikidata.org/wiki/Q4830453', 'display_name': 'Business', 'level': 0, 'score': 0.45595765}], 'mesh': [{'descriptor_ui': 'D004345', 'descriptor_name': 'Drug Industry', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': True}, {'descriptor_ui': 'D007221', 'descriptor_name': 'Industry', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': True}], 'locations_count': 4, 'locations': [{'is_oa': False, 'landing_page_url': 'https://doi.org/10.4155/tde-2022-0066', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S89829989', 'display_name': 'Therapeutic Delivery', 'issn_l': '2041-5990', 'issn': ['2041-5990', '2041-6008'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320316', 'host_organization_name': 'Future Science Ltd', 'host_organization_lineage': ['https://openalex.org/P4310320316'], 'host_organization_lineage_names': ['Future Science Ltd'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, {'is_oa': True, 'landing_page_url': 'https://arrow.tudublin.ie/context/scschcpsart/article/1154/viewcontent/Industry_Update_October_2022.pdf', 'pdf_url': 'https://arrow.tudublin.ie/context/scschcpsart/article/1154/viewcontent/Industry_Update_October_2022.pdf', 'source': {'id': 'https://openalex.org/S4306402084', 'display_name': 'ARROW@Dublin Institute of Technology (Dublin Institute of Technology)', 'issn_l': None, 'issn': None, 'is_oa': True, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I115570527', 'host_organization_name': 'Dublin Institute of Technology', 'host_organization_lineage': ['https://openalex.org/I115570527'], 'host_organization_lineage_names': ['Dublin Institute of Technology'], 'type': 'repository'}, 'license': 'cc-by-sa', 'license_id': 'https://openalex.org/licenses/cc-by-sa', 'version': 'submittedVersion', 'is_accepted': False, 'is_published': False}, {'is_oa': True, 'landing_page_url': 'https://arrow.tudublin.ie/scschcpsart/137', 'pdf_url': 'https://arrow.tudublin.ie/cgi/viewcontent.cgi?article=1154&context=scschcpsart', 'source': {'id': 'https://openalex.org/S4306402084', 'display_name': 'ARROW@Dublin Institute of Technology (Dublin Institute of Technology)', 'issn_l': None, 'issn': None, 'is_oa': True, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I115570527', 'host_organization_name': 'Dublin Institute of Technology', 'host_organization_lineage': ['https://openalex.org/I115570527'], 'host_organization_lineage_names': ['Dublin Institute of Technology'], 'type': 'repository'}, 'license': 'cc-by-sa', 'license_id': 'https://openalex.org/licenses/cc-by-sa', 'version': 'submittedVersion', 'is_accepted': False, 'is_published': False}, {'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/36748673', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': {'is_oa': True, 'landing_page_url': 'https://arrow.tudublin.ie/context/scschcpsart/article/1154/viewcontent/Industry_Update_October_2022.pdf', 'pdf_url': 'https://arrow.tudublin.ie/context/scschcpsart/article/1154/viewcontent/Industry_Update_October_2022.pdf', 'source': {'id': 'https://openalex.org/S4306402084', 'display_name': 'ARROW@Dublin Institute of Technology (Dublin Institute of Technology)', 'issn_l': None, 'issn': None, 'is_oa': True, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I115570527', 'host_organization_name': 'Dublin Institute of Technology', 'host_organization_lineage': ['https://openalex.org/I115570527'], 'host_organization_lineage_names': ['Dublin Institute of Technology'], 'type': 'repository'}, 'license': 'cc-by-sa', 'license_id': 'https://openalex.org/licenses/cc-by-sa', 'version': 'submittedVersion', 'is_accepted': False, 'is_published': False}, 'sustainable_development_goals': [{'display_name': 'Partnerships for the goals', 'id': 'https://metadata.un.org/sdg/17', 'score': 0.52}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 2, 'referenced_works': ['https://openalex.org/W4302424974', 'https://openalex.org/W4306669306'], 'related_works': ['https://openalex.org/W4391375266', 'https://openalex.org/W4307515305', 'https://openalex.org/W4231340554', 'https://openalex.org/W3213789065', 'https://openalex.org/W3168296622', 'https://openalex.org/W3080576469', 'https://openalex.org/W2931838652', 'https://openalex.org/W2765153054', 'https://openalex.org/W2596173151', 'https://openalex.org/W1491839574'], 'abstract_inverted_index': {'Therapeutic': [0, 3178], 'DeliveryAhead': [1], 'of': [2, 18, 46, 100, 105, 124, 209, 216, 220, 231, 310, 349, 448, 464, 481, 487, 502, 513, 516, 524, 531, 548, 558, 569, 611, 625, 640, 673, 686, 725, 735, 759, 767, 804, 810, 854, 867, 875, 882, 893, 900, 928, 955, 1009, 1012, 1021, 1047, 1055, 1062, 1103, 1158, 1171, 1283, 1335, 1351, 1357, 1371, 1385, 1408, 1415, 1420, 1427, 1447, 1463, 1496, 1522, 1529, 1589, 1623, 1646, 1669, 1684, 1722, 1749, 1769, 1788, 1906, 1944, 1966, 1975, 2000, 2055, 2065, 2101, 2178, 2185, 2294, 2374, 2411, 2418, 2429, 2458, 2475, 2483, 2521, 2527, 2637, 2695, 2754, 2760, 2763, 2783, 2789, 2811, 2819, 2835, 2939, 2980, 3007, 3110, 3155, 3204, 3329, 3346, 3437], 'Print': [3, 3347], 'Industry': [4], 'NewsFree': [5], 'AccessIndustry': [6], 'Update,': [7], 'October': [8, 61, 194, 338, 454, 691, 831, 990, 1249, 1391, 1604, 1728, 1855, 2254, 2408, 2557, 2692], '2022Elaine': [9], 'HarrisElaine': [10], 'Harris': [11], '*Author': [12], 'for': [13, 152, 163, 228, 382, 424, 476, 505, 544, 642, 755, 801, 889, 952, 1019, 1044, 1088, 1203, 1264, 1354, 1547, 1766, 1869, 1971, 2035, 2037, 2072, 2191, 2245, 2249, 2268, 2291, 2314, 2333, 2349, 2361, 2453, 2469, 2751, 2808, 2871, 3060, 3160, 3179, 3189, 3210, 3230, 3234, 3353], 'correspondence:': [14], 'E-mail': [15], 'Address:': [16], '[email protected]://orcid.org/0000-0003-1538-9947School': [17], 'Chemical': [19], '&': [20, 977, 1234, 2878, 3376], 'BioPharmaceutical': [21], 'Science,': [22], 'Technological': [23], 'University': [24, 2400], 'Dublin,': [25, 28], 'D07': [26], 'EWV4,': [27], 'IrelandPublished': [29], 'Online:7': [30], 'Feb': [31], '2023https://doi.org/10.4155/tde-2022-0066AboutSectionsPDF/EPUB': [32], 'ToolsAdd': [33], 'to': [34, 63, 159, 178, 223, 239, 400, 468, 551, 594, 607, 616, 635, 667, 716, 746, 750, 770, 779, 795, 818, 822, 841, 862, 895, 902, 904, 907, 930, 1002, 1041, 1094, 1114, 1121, 1136, 1154, 1189, 1217, 1227, 1279, 1294, 1328, 1375, 1492, 1503, 1518, 1542, 1557, 1642, 1675, 1707, 1863, 1876, 1929, 1982, 1997, 2025, 2044, 2087, 2109, 2141, 2150, 2172, 2193, 2203, 2236, 2265, 2287, 2309, 2391, 2438, 2471, 2502, 2525, 2573, 2593, 2602, 2611, 2626, 2661, 2668, 2729, 2779, 2852, 2950, 2966, 3004, 3010, 3039, 3114, 3147], 'favoritesDownload': [35], 'CitationsTrack': [36], 'CitationsPermissionsReprints': [37], 'ShareShare': [38], 'onFacebookTwitterLinkedInReddit': [39], 'Company': [40], 'newsBend': [41], 'Bioscience': [42, 49, 140, 2846, 2949], 'invests': [43], 'in': [44, 65, 69, 169, 171, 188, 250, 297, 321, 367, 405, 460, 564, 669, 704, 774, 864, 959, 1111, 1118, 1133, 1208, 1213, 1286, 1342, 1399, 1457, 1467, 1594, 1677, 1742, 1772, 1778, 1793, 1804, 1849, 1968, 2129, 2153, 2405, 2532, 2535, 2690, 2850, 2899, 2910, 2936, 3163, 3397, 3408, 3434], 'expansion': [45], 'drug-delivery': [47, 93, 332, 416, 982, 1024, 2080, 2549, 2837, 2855], 'capabilitiesBend': [48], '(OR,': [50], 'USA)': [51, 698, 1245, 1381, 1582, 1733, 2061, 2260, 2402, 2553], 'and': [52, 81, 85, 107, 110, 116, 150, 157, 211, 261, 293, 393, 407, 418, 522, 648, 757, 787, 812, 848, 870, 897, 960, 1007, 1101, 1126, 1140, 1151, 1162, 1221, 1229, 1303, 1309, 1689, 1705, 1818, 1821, 1845, 1893, 1939, 1942, 1952, 2004, 2015, 2082, 2093, 2167, 2170, 2176, 2215, 2225, 2232, 2317, 2346, 2365, 2446, 2485, 2516, 2628, 2664, 2792, 2844, 3051], 'NovaQuest': [53, 2942], 'Private': [54, 2943], 'Equity,': [55], 'have': [56, 278, 286, 303, 1000, 1983, 2403, 2434, 2711, 2806, 2847], 'announced': [57, 192, 335, 451, 699, 828, 987, 1196, 1246, 1382, 1734, 1852, 2062, 2252, 2554, 2832], 'plans': [58], 'on': [59, 76, 89, 193, 264, 329, 336, 420, 432, 452, 752, 829, 988, 1004, 1029, 1073, 1098, 1240, 1247, 1298, 1389, 1483, 1602, 1853, 2010, 2253, 2304, 2555, 2568, 2641, 2721, 2795, 2861, 3074, 3350], '11': [60], '2022': [62, 195, 339, 455, 832, 991, 1605, 1608, 1729, 1856, 2255, 2409, 2558, 2693, 2815, 3362], 'invest': [64], 'a': [66, 183, 201, 234, 290, 319, 379, 466, 471, 536, 545, 582, 612, 646, 670, 701, 705, 934, 1010, 1083, 1115, 1200, 1255, 1329, 1421, 1440, 1493, 1561, 1678, 1775, 1786, 1811, 1861, 1873, 1882, 1972, 2066, 2077, 2105, 2151, 2263, 2330, 2357, 2370, 2406, 2436, 2467, 2604, 2609, 2672, 2758, 2896, 3057, 3394], 'new': [67, 78, 96, 161, 255, 351, 671, 1179, 2651, 2655], 'facility': [68, 97], 'Bend,': [70], 'Oregon.': [71], 'The': [72, 190, 254, 276, 300, 588, 1275, 1315, 1435, 1513, 1539, 1808, 1908, 2097, 2118, 2157, 2432, 2598, 2615, 2659], 'group': [73, 2710], 'will': [74, 98, 119, 141, 257, 377, 498, 792, 1325, 1699, 1910, 1991, 2020, 2099, 2222, 2281, 2355, 2541, 2623, 2675], 'focus': [75], 'developing': [77], 'R&D': [79], 'partnerships,': [80], 'early': [82, 2128], 'phase': [83, 1441, 1719, 1739, 1812, 2050], 'manufacturing': [84, 115, 151], 'development': [86, 185, 1006, 1046, 1145, 1949, 2417], 'activities': [87], 'based': [88, 187, 263, 1848], 'proprietary': [90, 242, 308, 597, 912, 1430, 1915, 2135, 2371, 2563], 'particle': [91, 1937], 'engineering-based': [92], 'technologies.': [94], 'This': [95, 1791, 2913, 3411], 'consist': [99, 2100], 'approximately': [101], '20,000': [102], 'square': [103], 'feet': [104], 'laboratory': [106], 'processing': [108], 'areas': [109], 'it': [111, 197, 457, 541, 1252, 1822, 1858, 2123, 2448, 2560, 2653, 2804], 'is': [112, 262, 372, 492, 542, 581, 742, 763, 840, 860, 910, 1078, 1082, 1092, 1107, 1199, 1338, 1616, 1872, 1897, 2086, 2188, 2523, 2671, 2776], 'anticipated': [113], 'that': [114, 196, 280, 340, 374, 456, 494, 604, 651, 676, 700, 833, 936, 992, 1197, 1251, 1319, 1345, 1398, 1857, 1902, 2006, 2122, 2133, 2147, 2256, 2487, 2559, 2618, 2674, 2724, 2738, 2765, 2773, 2803], 'analytical': [117], 'capabilities': [118, 417], 'operational': [120], 'by': [121, 205, 825, 844, 973, 1080, 1322, 1453, 1490, 1933, 2228, 2380, 2478, 2588, 2698, 2739, 2787, 2824, 3042], 'the': [122, 128, 164, 170, 217, 229, 251, 307, 322, 327, 362, 397, 425, 433, 477, 485, 500, 506, 511, 528, 556, 559, 565, 609, 623, 626, 638, 665, 723, 780, 802, 815, 819, 834, 852, 855, 857, 865, 908, 953, 974, 1005, 1030, 1045, 1048, 1051, 1056, 1066, 1099, 1131, 1138, 1156, 1166, 1231, 1261, 1292, 1320, 1323, 1339, 1346, 1368, 1386, 1411, 1428, 1468, 1476, 1500, 1520, 1544, 1548, 1586, 1595, 1607, 1643, 1650, 1667, 1685, 1697, 1711, 1735, 1738, 1760, 1767, 1794, 1802, 1839, 1904, 1927, 1979, 1998, 2002, 2033, 2063, 2154, 2183, 2196, 2201, 2209, 2266, 2283, 2289, 2292, 2298, 2300, 2305, 2337, 2353, 2366, 2416, 2427, 2440, 2444, 2450, 2456, 2459, 2473, 2481, 2488, 2503, 2505, 2507, 2509, 2512, 2528, 2536, 2569, 2595, 2642, 2677, 2708, 2733, 2735, 2746, 2752, 2761, 2770, 2781, 2796, 2809, 2817, 2820, 2862, 2869, 2904, 2911, 2937, 3107, 3185, 3327, 3354, 3402, 3409, 3435], 'end': [123, 1413, 1418, 1515], 'Q2': [125], '2023.': [126], 'Announcing': [127], 'investment': [129, 874], 'decision,': [130, 726], 'Dan': [131], 'Dobry,': [132], 'Bend': [133, 139, 2845, 2948], "Bioscience's": [134], 'co-founder': [135], 'said': [136, 1173], '"We': [137, 1174], 'feel': [138], 'fill': [142], 'an': [143, 225, 764, 872, 878, 1017, 1119, 1526, 1566, 1617, 1672, 1842, 1865, 1900, 1964, 2189, 2713, 2833, 2859], 'unmet': [144, 584, 2359], 'need,': [145], 'offering': [146], 'problem': [147, 167], 'solving,': [148], 'formulation,': [149], 'valuable': [153], 'but': [154, 2030], 'challenging': [155], 'therapies': [156], 'collaborating': [158], 'develop': [160, 179, 224, 470], 'technologies': [162, 309], 'rapidly': [165], 'evolving': [166], 'statements': [168], 'pharmaceutical': [172], 'industry"': [173], '[1].Intravacc': [174], 'awarded': [175, 200, 729, 947, 969], 'US$14.6': [176, 202, 2962], 'million': [177, 203, 731, 737, 1043, 1064], 'intranasal': [180, 226, 2056, 2074], 'gonorrhoea': [181], 'vaccineIntravacc,': [182], 'vaccine': [184, 227, 252, 256], 'company': [186, 277, 314, 398, 426, 838, 1293, 1324, 1540, 1847, 2119, 2131, 2301, 2616, 2822], 'Bilthoven,': [189], 'Netherlands,': [191], 'had': [198, 346, 458, 719, 1194, 1253, 1859, 2261], 'been': [199, 304, 539, 720, 887, 968, 1555, 1963, 2139, 2161, 2586], 'contract': [204, 324], 'US': [206, 1262], 'National': [207, 218], 'Institute': [208], 'Allergy': [210], 'Infectious': [212], 'Diseases': [213], '(NIAID),': [214], 'part': [215], 'Institutes': [219], 'Health': [221], '(NIH)': [222], 'prophylaxis': [230], 'Neisseria': [232], 'gonorrhoeae,': [233], 'sexually': [235], 'transmitted': [236], 'disease.Intravacc': [237], 'intends': [238, 399], 'employ': [240], 'its': [241, 350, 403, 428, 1134, 1265, 1894, 2073, 2090, 2269, 2836, 2981], 'outer': [243], 'membrane': [244], 'vesicles': [245, 2592, 2599], '(OMV)': [246], 'platform': [247], 'deliver': [248, 2142, 2662], 'technology': [249, 837, 935, 1569, 2081, 2137, 2159, 2566, 2622, 3279], 'development.': [253], 'be': [258, 654, 823, 842, 863, 1326, 1877, 1911, 2023, 2282, 2492, 3040], 'named,': [259], 'NGoXIM,': [260], 'gonococcal': [265], 'OMVs': [266], 'combined': [267], 'with': [268, 272, 284, 289, 430, 707, 776, 877, 984, 1058, 1124, 1147, 1177, 1181, 1224, 1402, 1459, 1470, 1591, 1625, 1682, 1785, 1801, 1825, 1829, 1879, 1881, 2164, 2449, 2608, 2629, 2718, 2839, 2868, 2890, 2895, 2903, 3388, 3393, 3401], 'sustained-release': [269, 301], 'microspheres': [270], 'loaded': [271], 'recombinant': [273], 'human': [274, 1163], 'IL-12.': [275], 'reported': [279], 'initial': [281, 873, 2800], 'proof-of-concept': [282, 2052, 2067, 2084], 'studies': [283, 1312], 'NGoXIM': [285], 'indicated': [287, 769, 1318, 1397, 1774, 2121], 'efficacy': [288, 1308, 1817, 1896], 'potent,': [291], 'lasting': [292], 'cross-protective': [294], 'immune': [295, 2510], 'response': [296], 'animal': [298], 'models.': [299], 'microparticles': [302], 'developed': [305, 1079, 2435, 2562], 'employing': [306, 1913, 2111], 'Buffalo,': [311], 'New': [312, 1271, 2982, 3058], 'York-based': [313], 'Therapyx.': [315], 'Therapx': [316], 'are': [317, 1175, 2219, 2600, 2865], 'also': [318, 967, 1700, 1800], 'partner': [320], 'NIH/NAID': [323], '[2].Eisai': [325], 'cuts': [326], 'ribbon': [328], '$69M': [330], 'injectable': [331, 386, 473], 'facilityIt': [333], 'was': [334, 728, 827, 946, 986, 1130, 1277, 1437, 1451, 1517, 1798, 1810, 1823, 2251, 2766, 2934, 3432], '4': [337, 1530], 'Eisai': [341, 2843, 2977], 'Co.,': [342], 'Ltd': [343], '(Tokyo,': [344], 'Japan)': [345, 2705], 'completed': [347, 1712], 'construction': [348], 'injection/research': [352], 'building': [353], "'Eisai": [354], 'Medicine': [355], 'Innovation': [356], 'Technology': [357], "Solutions'": [358], "('EMITS')": [359], 'located': [360, 366], 'at': [361, 484, 555, 1536, 1560, 1606, 1659, 2089, 2398, 2985, 3136, 3165], 'Kawashima': [363, 2986], 'Industrial': [364, 2987], 'Park': [365, 2988], 'Gifu': [368], 'Prefecture,': [369], 'Japan.': [370, 2990], 'It': [371, 491, 1091, 1106], 'intended': [373, 493], 'this': [375, 495, 514, 532, 580, 1178, 1336, 1352, 1507, 1948, 1993, 2007, 2083, 2221, 2519, 2619, 2748, 2799, 2828, 2940, 3272, 3438], 'site': [376, 486, 557], 'provide': [378, 1280, 2204, 2466, 2499], 'global': [380], 'base': [381], 'formulation-based': [383], 'research': [384, 404, 2709], 'into': [385, 600, 2443, 2745], 'products': [387], 'facilitating': [388], 'therapeutic': [389, 1191, 1210, 1875, 1895, 1909, 1986, 2271], 'modalities': [390], 'including': [391, 427, 1149, 1160, 1936], 'antibodies': [392], 'antibody–drug': [394], 'conjugates.': [395], 'Additionally': [396, 884], 'further': [401, 412, 2194], 'expand': [402, 2853], 'liposomal': [406], 'lipid': [408, 1920, 3325], 'nanoparticle': [409], 'formulations.This': [410], 'announcement': [411], 'strengthens': [413], "Eisai's": [414], 'non-oral': [415], 'builds': [419], 'recent': [421, 1959], 'collaborative': [422], 'advances': [423], 'partnership': [429, 1180], 'Biogen': [431], "Alzheimer's": [434], 'disease': [435, 958, 1593, 1627, 2008], 'drug': [436, 2186, 2206, 2306, 2564, 2581, 2656, 3273, 3294], 'candidate': [437], 'lecanemab': [438], '[3].SURGE': [439], 'Therapeutics': [440, 526, 631, 683, 1362, 1378, 1716, 1731, 2998, 3022, 3101, 3146], 'raises': [441], '$26M': [442, 3000], 'series': [443, 465, 515], 'A': [444, 590, 1461, 3002], 'financingCambridge': [445], 'Massachusetts-based': [446], 'developer': [447], 'novel': [449, 472, 662, 2158, 2464], 'immunotherapeutics': [450, 483], '17': [453], 'succeeded': [459], 'raising': [461], '$26': [462], 'm': [463], 'financing': [467, 517, 591], 'help': [469, 771, 2223, 2392], 'biodegradable': [474, 941], 'hydrogel': [475, 507], 'targeted,': [478], 'localized': [479], 'delivery': [480, 508, 1157, 1844, 1932, 2187, 2340, 2368, 2428, 2565, 2582, 2657, 2684, 3274, 3295], 'cancer': [482, 549, 570, 617, 643, 674, 2727], 'surgical': [488, 658], 'tumour': [489], 'resection.': [490], 'funding': [496], 'round': [497], 'facilitate': [499, 1155], 'initiation': [501], 'clinical': [503, 601, 1311, 2053, 2070], 'trials': [504, 602, 1809], 'system.': [509, 3296], 'Discussing': [510], 'results': [512, 1396, 1651, 1709, 1758, 2127], 'Dr': [518, 1954], 'Michael': [519, 3246], 'Goldberg,': [520], 'CEO': [521, 788, 1170, 1953, 2177, 2636], 'Founder': [523, 1951], 'SURGE': [525, 630, 2997], 'contextualised': [527], 'possible': [529], 'benefits': [530], 'approach;': [533], '"Even': [534], 'after': [535, 619, 1070, 3084], 'tumor': [537, 561], 'has': [538, 606, 664, 886, 966, 1142, 1317, 1348, 1554, 1962, 2120, 2138, 2160, 2200, 2561, 2585, 2883, 3381], 'removed,': [540], 'common': [543], 'small': [546], 'number': [547], 'cells': [550, 2484, 2670], 'remain': [552], 'behind,': [553], 'whether': [554], 'primary': [560, 1412, 1417, 1514], 'or': [562, 1480, 1486, 1534, 2104, 2887, 2893, 2900, 2907, 2920, 2925, 2928, 2930, 3385, 3391, 3398, 3405, 3418, 3423, 3426, 3428], 'elsewhere': [563], 'body.': [566], 'Indeed,': [567], '40%': [568], 'patients': [571, 1123, 1400, 1409, 1458, 1465, 1477, 1508, 1523, 1590, 1624, 1880, 2224], 'who': [572, 1524, 1631], 'undergo': [573], 'surgery': [574], 'relapse': [575], 'within': [576, 1050], 'five': [577], 'years,': [578, 1960], 'so': [579, 603], 'major': [583], 'medical': [585, 836, 1976], 'need.': [586], '[….]': [587], 'Series': [589, 3001], 'enables': [592, 925], 'us': [593, 2192, 3349], 'advance': [595], 'our': [596, 808, 1187, 1204, 1984], 'intraoperative': [598], 'immunotherapies': [599], 'nobody': [605], 'grieve': [608], 'loss': [610], 'loved': [613], 'one': [614, 1020, 2526], 'owing': [615], 'recurrence': [618], 'surgery".': [620], 'Robert': [621], 'Langer,': [622], 'Chair': [624], 'Scientific': [627], 'Advisory': [628], 'Board,': [629], 'commented,': [632], '"SURGE': [633], 'seeks': [634], 'radically': [636], 'redefine': [637], 'process': [639, 1862, 1981], 'care': [641], 'patients,': [644], 'creating': [645], 'simple': [647], 'effective': [649, 2094], 'treatment': [650, 954, 1282, 1356, 1482, 1641, 1645, 1674, 1692, 1702, 1768, 1995, 2197, 2293], 'could': [652, 677], 'potentially': [653], 'administered': [655, 2108, 2214], 'during': [656, 1065], 'any': [657, 748, 2891, 3389], 'oncology': [659], 'procedure.': [660], "SURGE's": [661], 'approach': [663, 2680], 'potential': [666, 2202], 'usher': [668], 'pillar': [672], 'immunotherapy': [675], 'markedly': [678], 'enhance': [679, 1930, 2195, 2426, 2624], 'survival': [680], 'outcomes"': [681], '[4].Acorda': [682], 'announce': [684, 2049], 'findings': [685, 781, 1695, 2457], 'In': [687, 2296, 2732, 2947, 2989, 3029], 'AMPYRA®': [688, 762, 3030], 'arbitration': [689], 'caseOn': [690], '16': [692], '20022,': [693], 'Acorda': [694, 727, 741, 794, 3021], 'Therapeutics,': [695], 'Inc.': [696, 1243, 1580], '(NY,': [697, 2060, 2259], 'final': [702], 'decision': [703], 'dispute': [706], 'Alkermes': [708, 751], 'PLC': [709], '(Dublin,': [710], 'Ireland),': [711], 'regarding': [712], 'licensing': [713], 'royalties': [714, 749], 'relating': [715], 'AMPYRA': [717], '(dalfampridine)': [718], 'issued.': [721], 'Under': [722, 851], 'terms': [724, 853], '$15': [730], 'plus': [732], 'prejudgment': [733], 'interest': [734, 1967, 2898, 3396], '$1.5': [736], 'from': [738, 940, 1036, 1260, 1367, 1574, 1696, 1710, 1718, 1737, 1759, 1838, 2382, 3151], 'Alkermes.': [739], 'Additionally,': [740], 'no': [743, 2884, 3382], 'longer': [744], 'obliged': [745], 'pay': [747], 'net': [753], 'sales': [754], 'license': [756], 'supply': [758, 803, 1008, 1295], 'AMPYRA.': [760], "Acorda's": [761, 785], 'extended-release': [765, 1433, 1647], 'formulation': [766, 2373], 'dalfampridine': [768], 'improve': [772, 1127, 1222, 2237, 2632], 'walking': [773], 'adults': [775], 'multiple': [777], 'sclerosis.Reacting': [778], 'Ron': [782], 'Cohen,': [783], 'MD,': [784, 1655], 'President': [786], 'said,': [789], '"This': [790, 2326], 'award': [791], 'allow': [793], 'obtain': [796, 1864, 1987], 'more': [797], 'competitive': [798], 'market': [799, 2290, 2627], 'rates': [800], 'AMPYRA,': [805], 'significantly': [806], 'reducing': [807, 2212], 'cost': [809, 2621], 'goods': [811], 'meaningfully': [813], 'increasing': [814], "product's": [816], 'value': [817], 'company"': [820], '[5].MedAlliance': [821], 'acquired': [824, 843], 'CordisIt': [826], '19': [830], 'Geneva-based': [835], 'MedAlliance': [839, 2823, 3038], 'Cordis': [845], '(Baar,': [846], 'Switzerland,': [847], 'CA,': [849], 'USA).': [850], 'agreement,': [856], 'financial': [858, 2888, 2897, 2901, 3386, 3395, 3399], 'consideration': [859, 1683], 'thought': [861, 2042], 'order': [866], '$1.135': [868], 'Billion': [869], 'include': [871, 1034], '$35M': [876], 'upfront': [879], 'closing': [880], 'payment': [881], '$200M.': [883], 'provision': [885], 'made': [888, 939], 'regulatory': [890, 1235, 1238, 1980], 'achievement': [891], 'milestones': [892, 899], 'up': [894, 901, 929, 1040], '$125M': [896], 'commercial': [898, 1076], '$775M': [903], '2029.': [905], 'Key': [906], 'acquisition': [909, 2818], "MedAlliance's": [911], 'sustained': [913, 2347], 'sirolimus': [914], 'drug-eluting': [915], 'balloon': [916], '(DEB)': [917], 'program,': [918], 'SELUTION': [919, 944, 964], 'SLR™': [920], '(sustained': [921], 'limus': [922], 'release),': [923], 'which': [924, 1450, 2342, 2424], 'extended': [926, 1725], 'release': [927, 1543, 1558, 2348], '90': [931], 'days': [932], 'utilizing': [933], 'involves': [937], 'MicroReservoirs™': [938], 'polymer.In': [942], '2020': [943], 'SLR': [945, 965], 'CE': [948], 'Mark': [949], 'Approval': [950], 'both': [951, 2165, 2842], 'peripheral': [956], 'artery': [957, 962], 'coronary': [961], 'disease.': [963], 'four': [970], 'breakthrough': [971, 2390, 3275], 'designations': [972], 'FDA': [975, 1263, 1316, 1347, 2267, 3085], '[6].Collaborations': [976], 'agreementsMerck': [978], 'KGaA': [979, 1038, 2831], 'extends': [980], 'smart': [981], 'pact': [983], 'BIOCORPIt': [985], '10': [989, 1248], 'BIOCORP': [993, 1141, 1172, 3050], '(Paris,': [994], 'France)': [995], 'Merck': [996, 1022, 1037, 1182, 2830, 3052], 'KGaA,': [997, 1183, 3053], '(Darmstadt,': [998], 'Germany)': [999], 'agreed': [1001], 'work': [1003, 2775], 'version': [1011], "BIOCORP's": [1013], 'device,': [1014, 1269, 2876], 'Mallya,': [1015], 'as': [1016, 1439, 1639, 1671, 2145], 'accessory': [1018], "KGaA's": [1023], 'pen': [1025, 1089], 'injectors.': [1026, 1090], 'Financial': [1027], 'details': [1028], 'agreement': [1031, 1167, 2838], 'released': [1032], 'indicate': [1033], 'payments': [1035], 'of,': [1039], '€5': [1042], 'product': [1049], 'first': [1052, 1067, 1132, 2246, 2284, 3231], '3': [1053], 'years': [1054, 1069, 1344, 3083], 'collaboration': [1057, 1188], 'additional': [1059, 1190, 1296, 1307, 2774], 'revenues': [1060], 'accruing': [1061], '€8': [1063], '5': [1068], 'launch': [1071], 'depending': [1072], 'achieving': [1074], 'certain': [1075], 'milestones.Mallya': [1077], 'BIOCORP,': [1081], 'Bluetooth': [1084], 'enabled': [1085], 'clip-on': [1086], 'device': [1087, 1206, 1276, 1299, 1353, 3088], 'designed': [1093, 1278, 1438, 1556, 1824, 2140, 2587], 'collect': [1095], 'specific': [1096], 'information': [1097, 1110, 1297], 'dose': [1100, 1426, 1495, 1528, 2213], 'time': [1102, 1113, 1341], 'each': [1104], 'injection.': [1105], 'then': [1108, 1510], 'transfers': [1109], 'real': [1112], 'companion': [1116], 'software': [1117], 'effort': [1120], 'support': [1122], 'self-injections': [1125], 'compliance.': [1128], 'Mallya': [1129, 1207, 1215], 'category': [1135], 'receive': [1137], 'CE-mark': [1139], 'already': [1143, 1195, 2496], 'concluded': [1144], 'agreements': [1146], 'companies': [1148], 'Sanofi': [1150], 'Novo': [1152], 'Nordisk': [1153], 'therapeutics': [1159, 1846, 1970, 2036, 2572], 'insulin': [1161], 'growth': [1164], 'hormone.Announcing': [1165], 'Éric': [1168], 'Dessertenne,': [1169], 'delighted': [1176], 'Darmstadt,': [1184, 3054], 'Germany,': [1185, 3055], 'extending': [1186], 'areas.': [1192, 1211], 'We': [1193, 2218, 2335, 2495], 'there': [1198, 1961], 'great': [1201], 'opportunity': [1202, 2190], 'connected': [1205], 'various': [1209], 'As': [1212], 'diabetes,': [1214], 'aims': [1216], 'reduce': [1218, 2310], "patients'": [1219], 'stress': [1220], 'compliance': [1223], 'their': [1225, 1690, 1750, 2134, 2722, 2854, 2873], 'treatments': [1226], 'optimize': [1228], 'secure': [1230], 'results"': [1232], '[7].Approvals': [1233], 'updatesSupernus': [1236], 'provides': [1237, 2343], 'update': [1239, 2860], 'SPN-830Supernus': [1241], 'Pharmaceuticals,': [1242], '(MD,': [1244, 1380], '2022,': [1250], 'received': [1254, 2927, 3425], 'Complete': [1256], 'Response': [1257], 'Letter': [1258], '(CRL)': [1259], 'investigational': [1266, 1751, 2872], 'apomorphine': [1267, 2874], 'infusion': [1268, 2875, 3087], 'SPN-830,': [1270], 'Drug': [1272, 1835, 1867, 1989, 2114, 3062, 3191, 3215], 'Application': [1273], '(NDA).': [1274], 'continuous': [1281, 1355], 'motor': [1284, 1358], 'fluctuations': [1285, 1359], "Parkinson's": [1287, 1592, 1626, 3092, 3127], 'disease.The': [1288], "FDA's": [1289], 'communication': [1290], 'requires': [1291], 'manufacturing,': [1300], 'performance,': [1301], 'quality': [1302], 'risk': [1304], 'analysis.': [1305], 'No': [1306], 'safety': [1310, 1819], 'were': [1313, 1509, 1632, 2378], 'requested.': [1314], 'resubmission': [1321], 'subject': [1327, 2905, 3403], '6': [1330, 2407], 'month': [1331, 2829], 'review': [1332], 'timeline.': [1333], 'Receipt': [1334], 'CRL': [1337], 'second': [1340], '2': [1343, 1502, 1891, 3082, 3153], 'refused': [1349], 'approval': [1350, 2244, 3229], '[8,9].Clinical': [1360], 'trialsUnited': [1361], 'announces': [1363], 'top': [1364, 2125], 'line': [1365, 1394, 2126], 'data': [1366, 1573, 1584, 1717, 1736, 2303], 'EXPEDITE': [1369, 1387, 3108], 'study': [1370, 1388, 1395, 1436, 1446, 1469, 1615, 1622, 1665, 1698, 1820, 2085, 2801], 'remodulin': [1372], 'induction': [1373], 'prior': [1374], 'Orenitram': [1376, 1431, 1455, 1527, 1552, 3115], 'therapyUnited': [1377], 'Corporation': [1379], 'preliminary': [1383], 'analysis': [1384], '31': [1390, 2691], '2022.': [1392, 3138], 'Top': [1393, 3103], 'suffering': [1401, 2005], 'pulmonary': [1403, 1744], 'arterial': [1404], 'hypertension': [1405, 2316], '(PAH),': [1406], '79%': [1407], 'achieved': [1410, 1525], 'point': [1414, 1419, 1516], "study's": [1416], '12': [1422, 1854], 'mg': [1423, 1531], 'total': [1424, 1462], 'daily': [1425, 1533], "company's": [1429], '(treprostinil)': [1432, 1553], 'tablet.': [1434], 'IV,': [1442], 'multicenter,': [1443, 1620], 'open-label': [1444, 1577], '16-week': [1445], 'Remodulin': [1448, 1488, 3111], 'induction,': [1449], 'followed': [1452, 1489], 'oral': [1454, 1723], 'optimization': [1456], 'PAH.': [1460], '36': [1464], 'enrolled': [1466, 1475], '29': [1471], 'completing': [1472], 'it.': [1473], 'Once': [1474], 'began': [1478], 'in-patient': [1479], 'out-patient': [1481], 'either': [1484, 2102], 'intravenous': [1485], 'subcutaneous': [1487], 'titration': [1491], 'minimum': [1494], '20': [1497], 'ng/kg/min': [1498], 'over': [1499], 'next': [1501], '8': [1504, 3360], 'weeks.': [1505], 'Following': [1506], 'transitioned': [1511], 'to.': [1512, 2494], 'evaluate': [1519], 'percentage': [1521], 'three-times': [1532], 'higher': [1535], 'week': [1537], '16.': [1538], 'expect': [1541], 'full': [1545], 'dataset': [1546], 'EXPIDITE': [1549], 'trial': [1550, 1721, 1741, 1765, 2054, 2071, 2098], 'shortly.': [1551], 'treprostinil': [1559], 'near': [1562], 'zero-order': [1563], 'rate': [1564], 'using': [1565, 2716, 2757], 'osmotic': [1567], 'tablet': [1568], '[10].Neurocrine': [1570], 'Biosciences': [1571, 1661, 3124], 'presents': [1572], 'ONGENTYS®': [1575, 1670, 3132], '(opicapone)': [1576, 1637, 3133], 'studyNeurocrine': [1578], 'Biosciences,': [1579], '(CA,': [1581], 'presented': [1583], 'detailing': [1585], 'baseline': [1587], 'characteristics': [1588, 1935], 'Opicapone': [1596], 'Treatment': [1597], 'Initiation': [1598, 3203], 'Open-Label': [1599, 3134], 'Study': [1600, 3109, 3135], '(OPTI-ON)': [1601], '24': [1603, 1779, 3364], 'American': [1609], 'Neurological': [1610], 'Association': [1611], 'Annual': [1612], 'Meeting': [1613], '(ANA2022).The': [1614], 'open-label,': [1618], 'single-arm,': [1619], '6-month': [1621], 'experiencing': [1628], "'OFF'": [1629], 'episodes': [1630], 'prescribed': [1633], "Neurocrine's": [1634], 'once-daily': [1635, 2247, 2285, 3232], 'ONGENTYS': [1636], 'capsules': [1638], 'adjunctive': [1640], 'standard': [1644], 'carbidopa/levodopa': [1648, 1676], 'capsules.Discussing': [1649], 'Eiry': [1652], 'W': [1653], 'Roberts,': [1654], 'Chief': [1656, 2322], 'Medical': [1657], 'Officer': [1658, 2324], 'Neurocrine': [1660, 3123], 'stated': [1662], '"The': [1663], 'OPTI-ON': [1664], 'evaluated': [1666], 'use': [1668], 'adjunct': [1673], 'real-world': [1679], 'setting,': [1680], 'beginning': [1681], 'varied': [1686], 'patient': [1687, 2633], 'types': [1688, 2482], 'existing': [1691], 'regimens.': [1693], 'Full': [1694], 'examine': [1701], 'patterns,': [1703], 'safety,': [1704, 2091], 'tolerability': [1706, 2092], 'complement': [1708], 'pivotal': [1713], 'trials"': [1714], '[11].Trevi': [1715], 'II': [1720, 1740], 'nalbuphine': [1724, 1755], 'releaseOn': [1726], '27': [1727], 'Trevi': [1730, 3145], '(CT,': [1732], 'idiopathic': [1743], 'fibrosis': [1745], '(IPF)': [1746], 'chronic': [1747, 1770], 'cough': [1748, 1771, 1781, 1796, 1806], 'therapy': [1752], 'Haduvio™': [1753], '(oral': [1754], 'ER).': [1756], 'Top-line': [1757], 'CANAL': [1761], '(Cough': [1762], 'And': [1763, 3026], 'NALbuphine)': [1764], 'IPF': [1773, 3164], '76.1%': [1776], 'reduction': [1777, 1792, 1803], 'h': [1780], 'frequency': [1782, 1797], 'when': [1783], 'compared': [1784], '25.3%': [1787], 'placebo': [1789, 2106], 'subjects.': [1790], '24-h': [1795], 'consistent': [1799], 'daytime': [1805], 'frequency.': [1807, 2217], 'II,': [1813], 'double-blind,': [1814], 'randomized,': [1815], 'placebo-controlled': [1816], 'two-treatment,': [1826], 'two-period': [1827], 'crossover': [1828], '38': [1830], 'participants': [1831], '[12].SiSaf': [1832], 'seek': [1833], 'Orphan': [1834, 1866, 1988, 3190], 'Designation': [1836, 1868, 1990], 'status': [1837], 'FDASiSaf': [1840], 'Ltd,': [1841], 'RNA': [1843, 1969, 2571, 2596, 2663, 3177], 'Guilford,': [1850], 'England': [1851], 'initiated': [1860], 'SIS-101-ADO.': [1870], 'SIS-101-ADO': [1871, 2014], 'siRNA': [1874, 1901, 1931], 'trialled': [1878], 'rare': [1883, 2027, 2039], 'genetic': [1884], 'skeletal': [1885, 2028], 'disorder;': [1886], 'Autosomal': [1887], 'Dominant': [1888], 'Osteopetrosis': [1889], 'Type': [1890], '(ADO2),': [1892], 'mediated': [1898], 'through': [1899], 'suppress': [1903], 'expression': [1905], 'CLCN7.': [1907], 'facilitated': [1912], "SiSaf's": [1914, 3175], 'Bio-Courier®': [1916, 1925, 2017], 'silicon': [1917], 'stabilized': [1918], 'hybrid': [1919], 'nanoparticles': [1921], '(sshLNP)': [1922], 'technology.': [1923], "SiSAf's": [1924], 'offers': [1926], 'ability': [1928, 2308, 2660], 'modifying': [1934], 'size': [1938], 'surface': [1940, 1946, 2723], 'charge': [1941], 'addition': [1943], 'targeting': [1945, 2606, 2631], 'ligands.Announcing': [1947], 'SiSaf': [1950], 'Suzanne': [1955], 'Saffie-Siebert': [1956], 'commented:': [1957], '"In': [1958], 'explosion': [1965], 'wide': [1973], 'range': [1974], 'concerns.': [1977], 'Initiating': [1978], 'ADO2': [1985], 'move': [1992], 'revolutionary': [1994], 'closer': [1996], 'goal': [1999], 'alleviating': [2001], 'pain': [2003], 'inflicts': [2009], 'people.': [2011], 'Provided': [2012], 'successful,': [2013], 'other': [2016, 2038], 'formulated': [2018, 2144], 'drugs': [2019, 2666], 'not': [2021, 2649], 'only': [2022], 'able': [2024], 'treat': [2026], 'disorders': [2029], 'can': [2031, 2425, 2491], 'clear': [2032], 'way': [2034, 2678], 'diseases': [2040, 2646], 'once': [2041], 'impossible': [2043], 'treat"': [2045], '[13].atai': [2046], 'Life': [2047, 2058, 2180, 3200], 'Sciences': [2048, 2059, 3201], 'I': [2051], 'INB-01atai': [2057], 'commencement': [2064], '(phase': [2068], '1)': [2069], 'INB-01.': [2075], 'INB-01,': [2076], 'sol-gel': [2078], 'based,': [2079], 'look': [2088], 'brain': [2095], 'delivery.': [2096, 2614], 'INB-01': [2103, 2136, 2199], 'being': [2107], 'volunteers': [2110], 'Aptar': [2112], 'Nasal': [2113], 'Delivery': [2115, 3216, 3305], 'Device': [2116], '(www.aptar.com/pharmaceutical/delivery-routes/nasal-device-drug-delivery-oindp/).': [2117], 'expects': [2124], '2023.The': [2130], 'claim': [2132, 2617, 2737], 'actives': [2143], 'solutions': [2146], 'instantaneously': [2148], 'transform': [2149, 2439], 'gel': [2152], 'nasal': [2155], 'cavity.': [2156], 'successfully': [2162, 2278], 'utilized': [2163, 2935, 3433], 'water-soluble': [2166], 'insoluble': [2168], 'compounds': [2169], 'extracts.According': [2171], 'Florian': [2173], 'Brand,': [2174], 'Co-Founder,': [2175], 'atai': [2179, 3199], 'Sciences:': [2181], '"Exploring': [2182], 'mechanism': [2184, 2607], 'experience.': [2198], 'superior': [2205], 'uptake': [2207], 'via': [2208], 'nose–brain': [2210], 'barrier,': [2211], 'dosing': [2216], 'confident': [2220], 'healthcare': [2226], 'practitioners': [2227], 'easing': [2229], 'administration,': [2230], 'dosing,': [2231], 'providing': [2233], 'faster': [2234], 'relief': [2235], 'compliance"': [2238], '[14].Visiox': [2239], 'Pharma': [2240, 2258, 2384, 3225], 'submits': [2241, 3226], 'NDA': [2242, 2264, 2327, 2870, 3227], 'seeking': [2243, 3228], 'brimonidine': [2248, 2275, 2286, 3233], 'glaucomaIt': [2250], 'Visiox': [2257, 2381, 3224], 'submitted': [2262], 'lead': [2270], 'candidate,': [2272], 'PDP-716': [2273, 2280], '(0.35%': [2274], 'tartrate).': [2276], 'If': [2277], 'approved': [2279], 'enter': [2288], 'glaucoma.': [2295, 3235], 'submitting': [2297], 'application': [2299], 'provided': [2302, 2858], "candidate's": [2307], 'inter-occular': [2311], 'pressure': [2312], '(IOP)': [2313], 'ocular': [2315], 'open': [2318], 'angle': [2319], 'glaucoma.Ryan': [2320], 'Bleeks,': [2321], 'Executive': [2323], 'stated:': [2325, 2462], 'submission': [2328], 'marks': [2329], 'significant': [2331, 2358], 'milestone': [2332], 'Visiox.': [2334], 'believe': [2336], 'patented': [2338], 'TearAct™': [2339, 2367], 'technology,': [2341, 2369], 'slow,': [2344], 'consistent,': [2345], 'IOP': [2350], 'control': [2351], 'throughout': [2352], 'day': [2354], 'address': [2356], 'need': [2360], 'glaucoma': [2362], 'patients."Both': [2363], 'PDP-716,': [2364], 'suspension': [2372], 'resin': [2375], 'microparticle-complexed': [2376], 'drug,': [2377], 'licensed': [2379], 'Sun': [2383], 'Advanced': [2385], 'Research': [2386], '[15].Early': [2387], 'stage': [2388], 'developmentDrug-delivery': [2389], 'gene': [2393, 2454, 3277], 'editing': [2394, 3278], 'technologyMirkin': [2395], 'et': [2396, 2700], 'al.': [2397, 2701], 'Northwestern': [2399], '(IL,': [2401], 'reported,': [2404], 'edition': [2410], 'J.': [2412, 3254, 3334], 'Am.': [2413, 3255], 'Chem.': [2414, 3256], 'Soc.,': [2415], 'nanostructures,': [2419], 'spherical': [2420], 'nucleic': [2421], 'acids': [2422], '(SNAs),': [2423], 'CRISPR/Cas9': [2430], 'systems.': [2431, 2658], 'team': [2433], 'methodology': [2437], 'Cas-9': [2441], 'protein': [2442], 'SNA': [2445], 'load': [2447], 'components': [2451], 'required': [2452, 2778], 'editing.Discussing': [2455], 'paper': [2460, 2689, 2734], 'Mirkin': [2461, 3248], '"These': [2463], 'nanostructures': [2465], 'path': [2468], 'researchers': [2470], 'broaden': [2472], 'scope': [2474], 'CRISPR': [2476, 2489, 3250, 3270], 'utility': [2477], 'dramatically': [2479], 'expanding': [2480], 'tissues': [2486], 'machinery': [2490], 'delivered': [2493], 'know': [2497], 'SNAs': [2498], 'privileged': [2500], 'access': [2501, 2522], 'skin,': [2504], 'brain,': [2506], 'eyes,': [2508], 'system,': [2511], 'GI': [2513], 'track,': [2514], 'heart': [2515], 'lungs.': [2517], 'When': [2518], 'type': [2520], 'coupled': [2524], 'most': [2529], 'important': [2530], 'innovations': [2531], 'biomedical': [2533], 'science': [2534], 'last': [2537], 'quarter-century,': [2538], 'good': [2539], 'things': [2540], 'follow"': [2542], '[16,17].Mercury': [2543], 'Bio': [2544, 2551, 2639, 3289], 'develops': [2545, 3290], 'advanced': [2546, 2580, 3291], 'highly': [2547, 2784, 3292], 'targeted': [2548, 2574, 3293], 'systemMercury': [2550], '(NM,': [2552], '26': [2556], 'focussed': [2567], 'improved': [2570], 'diseased': [2575], 'cells.': [2576, 2731, 3281], 'Mercury': [2577, 2638, 3288], "Bio's": [2578], 'biomolecular,': [2579], 'system': [2583, 2685, 2749], '(ADDS™)': [2584], 'engineer': [2589], 'naturally': [2590], 'occurring': [2591], 'encapsulate': [2594], 'therapeutics.': [2597], 'modified': [2601], 'display': [2603], 'cell-specific': [2605], 'view': [2610], 'improving': [2612], 'site-specific': [2613], 'low': [2620], 'speed': [2625], 'enhanced': [2630], 'outcomes.Bruce': [2634], 'McCormick,': [2635], 'commenting': [2640], 'announcement;': [2643], '"Curing': [2644], 'many': [2645], 'now': [2647], 'does': [2648], 'require': [2650], 'drugs;': [2652], 'needs': [2654], 'small-molecule': [2665], 'directly': [2667], 'target': [2669], 'reality': [2673], 'change': [2676], 'we': [2679], 'disease"': [2681], '[18].Efficient': [2682], 'nanovaccine': [2683], 'boosts': [2686], 'cellular': [2687, 2755], 'immunityA': [2688], 'Journal': [2694], 'Controlled': [2696], 'Release': [2697, 3159], 'Harada': [2699], '(Osaka': [2702], 'Metropolitan': [2703], 'University,': [2704], 'describes': [2706], 'how': [2707], 'synthesized': [2712], 'antigen': [2714, 2764], 'carrier,': [2715], 'liposomes': [2717], 'pH-responsive': [2719], 'polysaccharides': [2720], 'preferentially': [2725], 'transports': [2726], 'antigens': [2728], 'dendritic': [2730], 'authors': [2736, 2771], 'incorporating': [2740], 'positively': [2741], 'charged': [2742], 'cationic': [2743, 2793], 'lipids': [2744, 2794], 'liposomes,': [2747], 'allows': [2750], 'activation': [2753], 'immunity,': [2756], 'fraction': [2759], 'amount': [2762], 'previously': [2767], 'required.': [2768], 'Although': [2769], 'conclude': [2772], 'still': [2777, 2866], 'elucidate': [2780], 'mechanisms': [2782], 'adjuvant': [2785], 'effects': [2786], 'combination': [2788], 'polysaccharide': [2790, 3330], 'derivatives': [2791], 'liposome,': [2797], 'nonetheless': [2798], 'indicates': [2802], 'may': [2805], 'usefulness': [2807], 'design': [2810], 'lipid-based': [2812], 'nano-vaccines': [2813], '[19,20].SummaryOctober': [2814], 'saw': [2816], 'Swiss': [2821], 'US-based': [2825], 'Cordis.': [2826, 3043], 'Also': [2827], 'extension': [2834], 'BIOCORP.': [2840], 'Meanwhile': [2841], 'invested': [2848], 'heavily': [2849], 'facilities': [2851], 'capabilities.': [2856], 'Supernus': [2857, 3070], 'issues': [2863, 3089], 'they': [2864], 'encountering': [2867], 'SPN-830.Financial': [2877], 'competing': [2879, 3377], 'interests': [2880, 3378], 'disclosureThe': [2881, 3379], 'author': [2882, 3380], 'relevant': [2885, 3383], 'affiliations': [2886, 3384], 'involvement': [2889, 3387], 'organization': [2892, 3390], 'entity': [2894, 3392], 'conflict': [2902, 3400], 'matter': [2906, 3404], 'materials': [2908, 3406], 'discussed': [2909, 3407], 'manuscript.': [2912, 3410], 'includes': [2914, 3412], 'employment,': [2915, 3413], 'consultancies,': [2916, 3414], 'honoraria,': [2917, 3415], 'stock': [2918, 3416], 'ownership': [2919, 3417], 'options,': [2921, 3419], 'expert': [2922, 3420], 'testimony,': [2923, 3421], 'grants': [2924, 3422], 'patents': [2926, 3424], 'pending,': [2929, 3427], 'royalties.No': [2931, 3429], 'writing': [2932, 3430], 'assistance': [2933, 3431], 'production': [2938, 3436], 'manuscript.References1.': [2941], 'Equity': [2944], 'Announces': [2945, 3023, 3102, 3202], 'Investment': [2946], 'Broaden': [2951], 'CoreRx': [2952], 'Offering.': [2953], 'www.prnewswire.com/news-releases/novaquest-private-equity-announces-investment-in-bend-bioscience-to-broaden-corerx-offering-301645482.html': [2954], '(Accessed': [2955, 2972, 2992, 3016, 3033, 3045, 3065, 3077, 3095, 3118, 3140, 3170, 3194, 3219, 3237, 3264, 3283, 3298, 3311, 3340], 'November': [2956, 2973], '28th': [2957, 2974], '2022).Google': [2958, 2975, 2995, 3019, 3036, 3048, 3068, 3080, 3098, 3121, 3143, 3173, 3197, 3222, 3240, 3267, 3286, 3301, 3314, 3343], 'Scholar2.': [2959], 'Intravacc': [2960], 'Awarded': [2961], 'Million': [2963], 'NIH/NIAID': [2964], 'Contract': [2965], 'Develop': [2967], 'Intranasal': [2968], 'Gonorrhea': [2969], 'Vaccine.': [2970], 'www.prnewswire.com/news-releases/intravacc-awarded-us14-6-million-nihniaid-contract-to-develop-intranasal-gonorrhea-vaccine-301640988.html': [2971], 'Scholar3.': [2976], 'Completes': [2978], 'Construction': [2979], 'Injection/Research': [2983], 'Building': [2984], 'www.eisai.com/news/2022/news202273.html': [2991], '1st': [2993, 3017, 3034, 3046], 'December': [2994, 3018, 3035, 3047, 3067, 3079, 3097, 3120, 3142, 3172, 3196, 3221, 3239, 3266, 3285, 3300, 3313, 3342, 3361], 'Scholar4.': [2996], 'Raises': [2999], 'Financing': [3003], 'Accelerate': [3005], 'Development': [3006], 'Intraoperative': [3008], 'Immunotherapy': [3009], 'Improve': [3011], 'Survival': [3012], 'Outcomes': [3013], 'Post-Surgery.': [3014], 'www.businesswire.com/news/home/20221017005003/en/SURGE-Therapeutics-Raises-26M-Series-A-Financing-to-Accelerate-Development-of-Intraoperative-Immunotherapy-to-Improve-Survival-Outcomes-Post-Surgery': [3015], 'Scholar5.': [3020], '$16.5M': [3024], 'Award': [3025], 'Royalty/Supply': [3027], 'Relief': [3028], 'Arbitration.': [3031], 'https://ir.acorda.com/investors/investor-news/investor-news-details/2022/Acorda-Therapeutics-Announces-16.5M-Award-and-RoyaltySupply-Relief-in-AMPYRA-Arbitration-Case/default.aspx': [3032], 'Scholar6.': [3037], 'Acquired': [3041], 'www.prnewswire.com/news-releases/medalliance-to-be-acquired-by-cordis-301652154.html': [3044], 'Scholar7.': [3049], 'Sign': [3056], 'Partnership': [3059], 'Smart': [3061], 'Delivery.': [3063], 'www.businesswire.com/news/home/20221009005016/en/BIOCORP-and-Merck-KGaA-Darmstadt-Germany-Sign-a-New-Partnership-for-Smart-Drug-Delivery': [3064], '8th': [3066, 3078, 3096, 3119, 3141, 3171, 3195, 3220, 3238, 3265, 3284, 3299, 3312, 3341], 'Scholar8.': [3069], 'Provides': [3071], 'Regulatory': [3072, 3187], 'Update': [3073], 'SPN-830.': [3075], 'https://ir.supernus.com/news-releases/news-release-details/supernus-provides-regulatory-update-spn-830': [3076], 'Scholar9.': [3081], 'refusal,': [3086], 'sink': [3090], "Supernus'": [3091], 'filing.': [3093], 'www.fiercepharma.com/pharma/two-years-after-fda-refusal-infusion-device-issues-sink-supernus-parkinsons-filing': [3094], 'Scholar10.': [3099], 'United': [3100], 'Line': [3104], 'Data': [3105, 3150], 'From': [3106, 3131], 'Induction': [3112], 'Prior': [3113], 'Therapy.': [3116], 'www.businesswire.com/news/home/20221031005165/en/United-Therapeutics-Announces-Top-Line-Data-From-the-EXPEDITE-Study-of-Remodulin-Induction-Prior-to-Orenitram-Therapy': [3117], 'Scholar11.': [3122], 'Presents': [3125], 'Real-World': [3126], 'Disease': [3128], 'Patient': [3129], 'Characteristics': [3130], 'ANA': [3137], 'www.prnewswire.com/news-releases/neurocrine-biosciences-presents-real-world-parkinsons-disease-patient-characteristics-from-ongentys-opicapone-open-label-study-at-ana2022-301656404.html': [3139], 'Scholar12.': [3144], 'Present': [3148], 'Final': [3149], 'Phase': [3152, 3205], 'Trial': [3154, 3209], 'Oral': [3156], 'Nalbuphine': [3157], 'Extended': [3158], 'Chronic': [3161], 'Cough': [3162], "BTS'": [3166], 'Winter': [3167], 'Meeting.': [3168], 'www.prnewswire.com/news-releases/trevi-therapeutics-to-present-final-data-from-phase-2-trial-of-oral-nalbuphine-extended-release-for-chronic-cough-in-ipf-at-bts-winter-meeting-301660829.html': [3169], 'Scholar13.': [3174], 'Innovative': [3176], 'Rare': [3180], 'Genetic': [3181], 'Skeletal': [3182], 'Disorders': [3183], 'Begins': [3184], 'U.S.': [3186], 'Process': [3188], 'Designation.': [3192], 'www.prnewswire.com/news-releases/sisafs-innovative-rna-therapeutic-for-rare-genetic-skeletal-disorders-begins-the-us-regulatory-process-for-orphan-drug-designation-301647086.html': [3193], 'Scholar14.': [3198], '1': [3206], 'Proof-of-Concept': [3207], 'Clinical': [3208], 'Its': [3211], 'Sol-gel': [3212], 'Based': [3213], 'Direct-to-Brain': [3214], 'Technology.': [3217], 'https://ir.atai.life/news-releases/news-release-details/atai-life-sciences-announces-initiation-phase-1-proof-concept': [3218], 'Scholar15.': [3223], 'www.ophthalmologytimes.com/view/visiox-pharma-submits-nda-seeking-approval-for-first-once-daily-brimonidine-for-glaucoma': [3236], 'Scholar16.': [3241], 'Chi': [3242], 'Huang,': [3243], 'Zhenyu': [3244], 'Han,': [3245], 'Evangelopoulos,': [3247], 'CA.': [3249], 'Spherical': [3251], 'Nucleic': [3252], 'Acids.': [3253], 'Soc.': [3257], '144,': [3258], '41,': [3259], '18756–18760': [3260], '(2022)': [3261], 'doi:': [3262, 3338], '10.1021/jacs.2c07913': [3263], 'Scholar17.': [3268], "'Near-limitless": [3269], "therapies':": [3271], 'helps': [3276], 'infiltrate': [3280], 'https://geneticliteracyproject.org/2022/10/13/near-limitless-crispr-therapies-this-drug-delivery-breakthrough-helps-gene-editing-technology-infiltrate-cells/': [3282], 'Scholar18.': [3287], 'www.prnewswire.com/news-releases/mercury-bio-develops-new-biomolecular-drug-delivery-platform-301659879.html': [3297], 'Scholar19.': [3302], 'Efficient': [3303], 'Nanovaccine': [3304], 'System': [3306], 'Boosts': [3307], 'Cellular': [3308], 'Immunity.': [3309], 'www.newswise.com/articles/efficient-nanovaccine-delivery-system-boosts-cellular-immunity': [3310], 'Scholar20.': [3315], 'Eiji': [3316], 'Yuba,': [3317], 'Yuna': [3318], 'Kado,': [3319], 'Nozomi': [3320], 'Kasho,': [3321], 'Atsushi': [3322], 'Harada.': [3323], 'Cationic': [3324], 'potentiated': [3326], 'adjuvanticity': [3328], 'derivative-modified': [3331], 'liposome': [3332], 'vaccines.': [3333], 'Control.': [3335], 'Rel.': [3336], '(2022).': [3337], '10.1016/j.jconrel.2022.10.016': [3339], 'ScholarFiguresReferencesRelatedDetails': [3344], 'Ahead': [3345], 'Follow': [3348], 'social': [3351], 'media': [3352], 'latest': [3355], 'updates': [3356], 'Metrics': [3357], 'History': [3358], 'Received': [3359], 'Accepted': [3363], 'January': [3365], '2023': [3366, 3371, 3373], 'Published': [3367], 'online': [3368], '7': [3369], 'February': [3370], 'Information©': [3372], 'Newlands': [3374], 'PressFinancial': [3375], 'manuscript.PDF': [3439], 'download': [3440]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W4319333649', 'counts_by_year': [], 'updated_date': '2024-09-12T00:50:20.648018', 'created_date': '2023-02-08'}